Plectonic Biotech entered research collaboration with Evotec to develop new T-cell-engaging biologics for solid tumors.

Plectonic Biotech’s new class of programmable DNA-protein therapeutics function as molecular logic gates to selectively direct the immune response at the tumor cell. By applying our modular LOGIBODY® platform, we are building a pipeline of multi-specific T cell-engaging biologics designed to overcome off-target toxicity and exponentially improve the therapeutic impact of clinically validated immunotherapy targets. Initially focused on hematologic malignancies, our approach is designed to deliver an unprecedented level of precision and control to achieve a wider therapeutic window and improve patient outcomes in both liquid and solid tumors. Interested in learning more? Visit https://plectonic.com/